September 6, 2025
Neomera accepted into
MBC BioLabs
On September 6, 2025, Neomera was officially accepted into
MBC BioLabs, the premier life
science incubator in the Bay Area. With 8–10 applicants competing
for every lab space and a track record of member companies raising
over $20 billion in capital,
MBC BioLabs is widely regarded
as one of the most selective and impactful innovation ecosystems for
biotech startups.
Why it matters: Acceptance into
MBC BioLabs is not only a
major milestone but also a strong external validation of Neomera’s
potential. This gives us access to state-of-the-art lab space,
startup-friendly infrastructure, and an unparalleled network of
investors, mentors, and industry leaders. In such a competitive
environment, being chosen demonstrates both the scientific
credibility of our platform and the transformative potential of our
mission to tackle chronic pain and addiction.
August 30, 2025
Neomera accepted into
CDL – Advanced
Therapeutics Track
On August 30, 2025, Neomera was accepted into the
Creative Destruction Lab (CDL)
Advanced Therapeutics Track, a globally renowned program that
supports science-based startups with mentorship from leading
scientists, investors, and industry executives.
Why it matters:
CDL offers access
to a powerful global network and world-class mentorship. Our
participation validates Neomera’s vision and accelerates our journey
from discovery to clinical translation and commercialization.
July 30, 2025
Prof. Wing Hung Wong joins as AI Biomedical Engineering Advisor
On July 30, 2025, Neomera signed Prof. Wing Hung Wong, a pioneer in
biostatistics and biomedical data science, as our AI Biomedical
Engineering Advisor. Prof. Wong’s groundbreaking contributions to
statistical genomics and AI modeling will help refine our discovery
algorithms and enhance target selectivity.
Why it matters: Our AI-driven platform is
central to Neomera’s competitive advantage. Prof. Wong’s expertise
will expand our ability to model complex biological systems, reduce
screening time, and unlock new therapeutic opportunities that were
previously inaccessible.
July 28, 2025
Dr. Peter Schmit joins as Clinical Advisor
On July 28, 2025, Neomera appointed Dr. Peter Schmit as Clinical
Advisor. Dr. Schmit brings extensive experience in pain medicine and
clinical development strategy. His expertise will help design robust
clinical pathways, ensuring that our candidates are positioned for
successful translation from lab to patients.
Why it matters: Clinical trial design and
execution are critical bottlenecks in pain drug development. Dr.
Schmit’s leadership enables us to anticipate challenges, optimize
endpoints, and accelerate timelines for bringing safe, effective
therapies to patients.
July 17, 2025
Dr. Frank Bosmans joins as Scientific Advisor
On July 17, 2025, Neomera welcomed Dr. Frank Bosmans, an
internationally recognized leader in ion channel biology, as our
Scientific Advisor. Dr. Bosmans’ expertise in sodium channel
pharmacology and pain signaling mechanisms will be instrumental in
guiding our lead NaV1.8/1.9 program. His insights ensure our
discovery platform remains at the forefront of mechanistic rigor and
translational science.
Why it matters: Pain biology is complex,
and targeting NaV1.9 has long been considered “undruggable.” Having
Dr. Bosmans’ guidance strengthens our ability to navigate these
challenges with confidence and scientific precision.
